Atrial Leadless Pacemakers - Exclusively from Abbott
In patients with sinus node dysfunction (SND) and preserved atrioventricular (AV) conduction, the AVEIR AR2 Atrial Leadless Pacemaker (LP) offers a more physiological approach to pacing by initiating atrial activation and maintaining AV synchrony through the native conduction system1 while helping reduce the risk of atrial fibrillation (AF), heart failure (HF) and pacing-induced cardiomyopathy.2-5
Expanding Abbott’s leadless platform, the AVEIR AR2 Atrial LP with enhanced longevity is designed for long-term therapy and future adaptability.
AVEIR AR2 Atrial LP offers these key benefits over AVEIR AR Atrial LP without increasing device size:
When paired with the AVEIR VR Ventricular LP, the AVEIR AR2 Atrial LP forms the AVEIR DR Dual Chamber System, which can be programmed to DDD(R) or AAI(R)+VVI.
For patients with complete heart block, DDD(R) pacing is available by enabling implant-to-implant (i2iTM) communication between the devices to provide continuous average AV synchrony above 95% in all postures.7
For patients with sinus node dysfunction that might benefit from ventricular back-up pacing, AAI(R)+VVI is available with implant-to-implant (i2i) communication turned off, providing increased battery life for both devices.6
Compared with dual chamber transvenous pacemakers (TVPs), AVEIR AR Atrial LP significantly reduced11
Overall
complications by 60%
(3.6% vs. 8.5%, p<0.01, adjusted)
Device-related complications by 50%
(3.5% vs. 7.4%, p<0.01, adjusted)
Device-related reinterventions by 60%
(1.8% vs. 4.5%, p=0.01, adjusted)
ELECTRICAL PERFORMANCE SUCCESS RATE AT 3 MONTHS for patients with acceptable atrial device pacing capture threshold (≤ 3 V at 0.4 ms) and sensing amplitude (≥ 1 mV)**,7
95.2% 3-month atrial composite success rate with modified sensing criteria (≥ 0.5 mV)8,***
FREEDOM FROM COMPLICATIONS AT 3 MONTHS.7 The inclusion of arrhythmias as a safety endpoint increased the overall incidence of complications compared with other studies of leadless pacemakers, which excluded arrhythmias from the endpoint.
***Multiple imputation used for missing data
AVEIR LPs have an active helix fixation that uses a screw-in mechanism to enable both implantation and long-term retrieval of the atrial and ventricular devices at end-of-service (EOS).6
AVEIR AR Atrial LP Retrieval Data (n=10)10
successful atrial device retrievals
± 9.2 average minutes retrieval procedure time
± 6.6 average months from implant to retrieval (dwell time)
Dr. Kent Nilsson discusses his experience using the AVEIR™ AR Atrial LP for patients with sinus node dysfunction (SND), highlighting its advantages over TVPs.
He reviews real-world data showing that AVEIR AR Atrial LP has lower 30-day complications compared to dual chamber transvenous systems and similar short-term outcomes to right-atrial devices. At one year, AVEIR AR Atrial LP demonstrated significantly fewer complications and reinterventions than both transvenous approaches, with comparable mortality.
Dr. Nilsson concludes that for appropriate SND patients without AV block, AVEIR AR Atrial LP offers a safer, less invasive alternative with improved long-term outcomes.
New evidence suggests hardware avoidance itself may be a compelling therapeutic objective in selected sinus node dysfunction (SND) patients. See the evidence showing significantly fewer complications with AVEIR™ AR Atrial Leadless Pacemakers.
Real-world data demonstrated that the combination of AAI pacing and leadless pacemaker technology offers a safer, more efficient treatment of sick sinus syndrome (SSS) over transvenous pacing methods.
Explore the ongoing debate between AAI and DDD pacing for sick sinus syndrome (SSS). Learn how guidelines, trials, and innovations like leadless pacemakers, such as the AVEIR™ AR Atrial LP, influence clinical decisions to improve outcomes for SSS patients.
Presentation at Heart Rhythm 2025 by Rajesh Banker, MD
Patient therapy can be tailored by implanting an atrial device alone, or both atrial and ventricular devices together for dual chamber support. The option to upgrade over time allows you to meet your patient’s needs today and adapt to common disease progression later.
Treatment Option 1: Start with the Atrial Device.
Treat atrial arrhythmia and sinus node dysfunction today.
Add a ventricular device for heart block later.
i2i™ communication is enabled.
Activate dual chamber pacing therapy DDD(R) via i2i communication.
Treatment Option 2: Start with a dual chamber DDD(R) system.
Start with a dual chamber system device.
Turn off Beat-to-Beat communications to enable independent single chamber pacing for each device.
Treat SND patients today with AAI(R)+VVI pacing in the case of rare intermittent AV block.
For additional information about specific MR Conditional, including warnings, precautions, adverse conditions to MRI scanning and potential adverse events, please refer to the MRI-Ready Leadless Systems Manual at medical.abbott/manuals or check our MRI-Ready resources at cardiovascular.abbott/mriready
† Note: AAI(R)+VVI mode should not be used in patients without intact AV node conduction, or with chronic atrial fibrillation or atrial flutter.
*AVEIR AR2 LP model LSP203A compared to predecessor AVEIR AR Atrial LP LSP201A: AAI(R) at 1.5 V, 300 ohms, 0.4 ms, 50 bpm, 100% atrial pacing. DDD(R) at: 1.5 V, 300 ohms, 0.4 ms, 50 bpm, 50% atrial pacing, i2i setting 4/46,9.
** AVEIR AR2 LP LSP203A: AAI(R) and AAI(R)+VVI at 1.5 V, 300 ohms, 0.4 ms, 50 bpm, 100% atrial pacing.
*** 1.5V, 0.4 ms, 60 bpm, 300 ohms, 100% A pacing, 10% V pacing, i2i™ settings = 4 / 46,9
REFERENCES
MAT-2616156 v4.0
